Child
Dosing Schedule3
0.25mL dose
Dosing Schedule3
0.25mL dose
Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Stationed Overseas?
Help Protect
Your Family.
If your family travels with you overseas to Europe or Asia, help to keep them safe from Tick-Borne Encephalitis (TBE).
Though rare, TBE is a potentially devastating viral disease, which is caused by a single tick bite that has the TBE virus.1 There is no cure for TBE, only management of symptoms.2,3 Vaccination can help prevent TBE for individuals spending time in Europe and Asia.1,2
Learn more about prevention and the importance of vaccination for military dependents and spouses.
Though rare, TBE is a potentially devastating viral disease, which is caused by a single tick bite that has the TBE virus.1 There is no cure for TBE, only management of symptoms.2,3 Vaccination can help prevent TBE for individuals spending time in Europe and Asia.1,2
Learn more about prevention and the importance of vaccination for military dependents and spouses.
Contact a physician at your Military Treatment Facility for more information.
Key Facts
>
0
countries* affected throughout
Europe and Asia2,4
Europe and Asia2,4
0
confirmed cases reported
in Europe and Asia in 20202
in Europe and Asia in 20202
0
-
0
%
suffering from severe disease
develop long-term
consequences5
develop long-term
consequences5
What is Tick-Borne Encephalitis?
Tick-borne encephalitis is a rare infection of the brain and spine.1 Transmission of the TBE virus to humans most commonly occurs from the bite of an infected tick.2 Symptoms typically appear in two phases and can be mistaken initially for a mild flu-like illness.4,6 The most common symptoms in the first phase are fever, fatigue, headache, and muscle pain.6 Those that progress to the second phase may experience symptoms similar to other causes of inflammation of the brain and spine or meningitis.6
Ticks infected with the TBE virus are not confined to one country, with reports of infected ticks from across Europe to Asia.7,8 TBE has been reported in more than 30 countries throughout Europe and Asia.2,4
Consequences of Infection
Tick-borne encephalitis can result in long-term consequences including disability, paralysis, and death.1,9 Among adults infected with the European subtype, two-thirds will only experience phase one.5 After about 8 days of no symptoms, 20-30% of patients will experience a second phase.5 Of those that experience both phases, between 30-60% will have long-term consequences.5 In rare cases and depending on the subtype of infection, death may occur.5
Who Can Be Affected?
Anyone traveling to a country* and participating in high-risk activities can be affected by TBE.4 Most TBE virus infections result from tick bites acquired in forested areas through activities such as camping, hiking, fishing, bicycling, collecting mushrooms, berries, or flowers, and outdoor occupations such as forestry or military training.4 The risk is negligible for people who remain in urban or unforested areas and who do not consume unpasteurized dairy products.4 Military personnel and their families stationed overseas or visiting endemic areas may be at risk.2,4
Who Should Get Vaccinated?
According to the World Health Organization, vaccination is considered the most effective prevention measure for TBE.10
Military personnel deployed to endemic areas should consider receiving vaccinations. Spouses and military dependents traveling to endemic areas are to receive vaccination before departure to help ensure protection against TBE infection.
You and your families should consider prevention options including vaccination if spending time outdoors in wooded or grassy areas, whether in an urban or rural area during TBE virus transmission season, or engaging in activities that will expose them to ticks.1,4
This includes:
Military personnel deployed to endemic areas should consider receiving vaccinations. Spouses and military dependents traveling to endemic areas are to receive vaccination before departure to help ensure protection against TBE infection.
You and your families should consider prevention options including vaccination if spending time outdoors in wooded or grassy areas, whether in an urban or rural area during TBE virus transmission season, or engaging in activities that will expose them to ticks.1,4
This includes:
- Traveling during warmer months when ticks are more active typically from April through November.4
- Spending a substantial amount of time outdoors in wooded or grassy areas.4
- Participating in outdoor activities, such as camping, hiking, fishing, bicycling, collecting mushrooms, berries, or flowers, and outdoor occupations such as forestry or military training.4
What You Should Know About The TicoVacTM Vaccine
TicoVac™ is a vaccine indicated for active immunization to prevent a disease caused by the TBE virus, approved for use in individuals one year of age and older.3 The primary TicoVacTM series should be completed at least 1 week prior to potential exposure to TBE.3
TicoVacTM follows a 3-dose schedule.3 The entire primary vaccination schedule can be completed in as few as 6 months for all individuals.3
TicoVacTM has an established safety and tolerability profile for both children and adults.3 The Pfizer TBE vaccine has been used for over 45 years outside of the US.11,12 The most common side effects for individuals 1 through 15 years of age are local tenderness, local pain, headache, fever, and restlessness.3 For individuals 16 through 65 years of age, the most common side effects are local tenderness, local pain, fatigue, headache, and muscle pain.3
TicoVacTM follows a 3-dose schedule.3 The entire primary vaccination schedule can be completed in as few as 6 months for all individuals.3
TicoVacTM has an established safety and tolerability profile for both children and adults.3 The Pfizer TBE vaccine has been used for over 45 years outside of the US.11,12 The most common side effects for individuals 1 through 15 years of age are local tenderness, local pain, headache, fever, and restlessness.3 For individuals 16 through 65 years of age, the most common side effects are local tenderness, local pain, fatigue, headache, and muscle pain.3
Contact a physician at your Military Treatment Facility for more information.
Child
Dosing Schedule3
0.25mL dose
Dosing Schedule3
0.25mL dose
Dose 1
Dose 2
1 to 3 months after
the first dose
1 to 3 months after
the first dose
Dose 3
5 to 12 months after
the second dose
5 to 12 months after
the second dose
Adult
Dosing Schedule3
0.5mL dose
Dosing Schedule3
0.5mL dose
Adult
Dosing Schedule3
0.5mL dose
Dosing Schedule3
0.5mL dose
Dose 1
Dose 2
14 days to 3 months
after the first dose
14 days to 3 months
after the first dose
Dose 3
5 to 12 months after
the second dose
5 to 12 months after
the second dose
If you’re an active-duty family member traveling with your sponsor on PCS orders or on official travel, you may be eligible for vaccine reimbursement.
CONTACT A TRICARE REPRESENTATIVE
* Albania, Austria, Belarus, Bosnia and Herzegovina, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Mongolia, Netherlands, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, South Korea, Sweden, Switzerland, Ukraine.4
References
- Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-1871.
- Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.
- TicoVacTM (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.
- Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017. Chapter 4. Accessed February 4, 2022. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis
- Centers for Disease Control and Prevention. Tick-borne encephalitis (TBE) Factsheet. Accessed February 4, 2022. https://www.cdc.gov/vhf/tbe/resources/TBE-FactSheet.pdf
- Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am. 2008;22(3):561-575.
- Bogovic P, Strle F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin
Cases. 2015;3(5):430-441. - European Centre for Disease Prevention and Control. Tick-borne encephalitis - Annual epidemiological report for 2018. Accessed
February 4, 2022. https://www.ecdc.europa.eu/en/publications-data/tick-borne-encephalitis-annual-epidemiological-report-2018 - European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE). Accessed February 4, 2022.
https://www.ecdc.europa.eu/en/tick-borne-encephalitis/facts/factsheet - World Health Organization Regional Office for Europe, European Centre for Disease Prevention and Control. Fact sheet - Tick - borne encephalitis in Europe. Accessed February 4, 2022. https://www.euro.who.int/en/about-us/whd/past-themes-of-world-health-day/2014-vector-borne-diseases/fact-sheets-world-health-day-2014-vector-borne-diseases/fact-sheet-tick-borne-encephalitis-in-europe
- Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine. 2003;21 (suppl 1):S41-S49.
- Data on file. Pfizer Inc. 2017.
IMPORTANT SAFETY INFORMATION AND INDICATION
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Indication
- TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
Important Safety Information
- TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™.
- TicoVac™ may not protect all individuals against TBE.
- Some individuals with weakened immune systems may have a reduced immune response.
- TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
- The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
- The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
- Tell your healthcare provider if you are pregnant, or plan to become pregnant.
- Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Please see full prescribing information for TicoVac™ here.
IMPORTANT SAFETY INFORMATION AND INDICATION
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Indication
- TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
Important Safety Information
- TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™.
- TicoVac™ may not protect all individuals against TBE.
- Some individuals with weakened immune systems may have a reduced immune response.
- TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
- The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
- The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
- Tell your healthcare provider if you are pregnant, or plan to become pregnant.
- Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Please see full prescribing information for TicoVac™ here.
